Dr. Reddy’s Laboratories Limited, NSE Symbol: DRREDDY, BSE Script Code: 500124, an integrated Pharmaceutical Company committed towards giving affordable and innovative medical services, along with its subsidiaries which is together known as Dr. Reddy’s launched of a store-brand medicine called over-the-counter (OTC) Olapatadine Hydrochloride Ophthalmic Solution USP, of 0.2% and 0.1% doses which serves as an equivalent to Pataday Twice Daily Relief and Pataday Once Daily Relief in the U.S. market. The medicines are approved by the U.S. Food and Drug Administration (USFDA).
Olapatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1% are Eye Allergy Drops which would provide a temporary relief during the conditions of itchy eyes caused by pollen, animal hair, dander etc. Besides, these also give temporary relief from red eyes. These 0.2% and 0.1% dosage solutions are available in a 2.5ml bottles and 5ml bottles respectively.
According to IRi the Pataday brand had total US sales of $31 million approximately since the launch in March 2020.
The CEO, North America Generics, Dr. Reddy’s remarked, “This launch marks the entry of Dr. Reddy’s into the OTC eye care space, and is a testament to our deep capabilities in bringing store-brand equivalents of Rx-to-OTC switches to the U.S. market.”